Mosaic ImmunoEngineering Company Description

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use.

Its lead immunotherapy product candidate is MIE-101 which is based on cowpea mosaic virus which is non-infectious in humans and animals.

The company was founded in 2020 and is based in Novato, California.

Mosaic ImmunoEngineering, Inc.

Country	United States
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Steven King

Contact Details

Address: 1537 South Novato Blvd, #5 Novato, Delaware 94947 United States
Phone	657 208 0890
Website	mosaicie.com

Stock Details

Ticker Symbol	CPMV
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US61945M1018
SIC Code	2836

Key Executives

Name	Position
Steven W. King	Chairman of the Board, President and Chief Executive Officer
Paul J. Lytle CPA	Executive Vice President, Chief Financial Officer, Secretary and Director
Joseph S. Shan M.P.H.	Head of Clinical Operations
Dr. Marvin R. Garovoy M.D.	Head of Medical Immuno-Oncology
Cyril Empig Ph.D.	Head of Vaccine Development